Guardant Health Inc
Slēgts
SektorsVeselības aprūpe
157.41 -0.3
Pārskats
Akcijas cenas izmaiņa
24h
Min
156.16
Max
158.93
Ienākumi | -8.1M -120M |
|---|---|
Pārdošana | 33M 335M |
EPS | -0.89 |
Peļņas marža | -35.866 |
Darbinieki | 2,490 |
EBITDA | -8.1M -109M |
Nākamie ieņēmumi | 2026. g. 28. okt. |
|---|
Tirgus kapitalizācija | 2.4B 22B |
|---|---|
Iepriekšējā atvēršanas cena | 157.71 |
Iepriekšējā slēgšanas cena | 157.41 |
Ziņu noskaņojums
By Acuity
50%
50%
136 / 339 Rangs Healthcare
Guardant Health Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Guardant Health Inc Prognoze
Noskaņojums
By Acuity
136 / 339 Rangs Veselības aprūpe
Ziņu noskaņojums
Neutral
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Vidējais
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.